This is a randomized controlled trial to explore the efficacy and safety of ND-12 combined with H-6 for patients with chronic inflammatory diarrhea
At least 36 subjects who meet all the inclusion criteria but do not meet any exclusion criteria will be enrolled in this study. They will be randomly assigned to the mesalazine group , ND-12, and the ND-12/H-6 group. Data of demographic characteristics, intestinal symptoms, medicine treatment usage and clinical outcomes will be collected. After treatment, they will enter the follow-up period for efficacy and safety evaluation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
36
Take 4 melesalazine capsules each time, 3 times a day. Continue for 14 days.
Take 1 ND-12 capsule and 3 blank capsules each time, 3 times a day. Continue for 14 days
Take 1 ND-12 capsule and 3 H-6 capsules each time, 3 times a day. Continue for 14 days
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
RECRUITINGFecal calprotectin of patients 14 days after treatment compared to the baseline level
The rate of change in fecal calprotectin levels of the subjects at 14 days compared to the baseline level
Time frame: baseline, 14 days post-drug administration
The proportion of subjects who achieved a clinical response on the 14th day
The proportion of subjects who achieved a clinical response on the 14th day(Fecal calprotectin decreased by ≥50% compared to the baseline or returned to normal \<150 μg/g)
Time frame: 14 days post-drug administration
The proportion of subjects achieving deep remission on the 14th day
The proportion of subjects achieving deep remission on the 14th day (Fecal calprotectin \< 100 μg/g)
Time frame: 14 days post-drug administration
Serum inflammatory factors after treatment
The changes in inflammatory factors (IL-1β, IL-10, TNF-α) in the blood of the subjects at 14 days compared to the baseline level
Time frame: baseline, 14 days post-drug administration
The frequency of defecation after treatment
The situation of the subjects' defecation frequency on the 7th, 14th, and 28th days compared to the baseline;
Time frame: baseline, 7 days post-drug administration, 14 days post-drug administration, and 28 days post-drug administration
The fecal consistency scores after treatment
The changes in the fecal consistency scores (measured using the Bristol Fecal Form Scale) of subjects on the 7th, 14th, and 28th days compared to the baseline;
Time frame: baseline, 7 days post-drug administration, 14 days post-drug administration, and 28 days post-drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The gastrointestinal symptom grading scores after treatment
The gastrointestinal symptom grading scores (using the GSRS scoring scale) of subjects on the 7th, 14th, and 28th days compared with the baseline values
Time frame: baseline, 7 days post-drug administration, 14 days post-drug administration, and 28 days post-drug administration
The changes of gut microbiome and metabolome
Changes in the gut microbiome and metabolome of subjects on the 7th day compared with baseline
Time frame: baseline, 7 days post-drug administration